Literature DB >> 10527461

Correlation between IL-3 receptor expression and growth potential of human CD34+ hematopoietic cells from different tissues.

S Huang1, Z Chen, J F Yu, D Young, A Bashey, A D Ho, P Law.   

Abstract

CD123 (alpha-subunit of IL-3 receptor) expression on primitive and committed human hematopoietic cells was studied by multicolor sorting and single-cell culture. The sources of cells included fetal liver (FLV), fetal bone marrow, umbilical cord blood, adult bone marrow and mobilized peripheral blood. Three subsets of CD34+ cells were defined by the levels of surface CD123: CD123negative, CD123low, and CD123bright. Coexpression of lineage markers showed that a majority of CD34+CD123bright cells were myeloid and B-lymphoid progenitors, while erythroid progenitors were mainly in the CD34+CD123negative subset. The CD34+CD123low subset contained a heterogeneous distribution of early and committed progenitor cells. Single CD34+ cells from the CD123 subsets were cultured in a cytokine cocktail of stem cell factor, interleukin 3 (IL-3), IL-6, GM-CSF, erythropoietin, insulin-like growth factor-1, and basic fibroblast growth factor. After 14 days of incubation, a higher cloning efficiency (CE) was observed in the CD34+CD123negative and CD34+CD123low fractions (37+/-23% and 44+/-23%, respectively) than in the CD34+CD123bright fraction (15+/-21%). Using previously published criteria that colonies containing dispersed, translucent cells (dispersed growth pattern, DGP) were derived from primitive cells and that colonies composed solely of clusters were from committed cells, early precursors were distributed evenly in the CD34+CD123negative and CD34+CD123low subsets. When CD38 and CD90 (Thy-1) were used for further characterization of CD34+ cells from FLV, CE increased from 37+/-23% in CD123negative to 70+/-19% in CD123negativeCD38- and from 44+/-23% in CD123low to 66+/-19% in CD123lowCD38-. No significant increase in CE or DGP progenitors was observed when CD34+ cells were sorted by CD90 and CD123. We concluded that: A) high levels of CD123 were expressed on B-lymphoid and myeloid progenitors; B) early erythroid progenitors had little or no surface CD123, and C) primitive hematopoietic cells are characterized by CD123negative/low expression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10527461     DOI: 10.1002/stem.170265

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  16 in total

1.  Isolation and transcriptome analyses of human erythroid progenitors: BFU-E and CFU-E.

Authors:  Jie Li; John Hale; Pooja Bhagia; Fumin Xue; Lixiang Chen; Julie Jaffray; Hongxia Yan; Joseph Lane; Patrick G Gallagher; Narla Mohandas; Jing Liu; Xiuli An
Journal:  Blood       Date:  2014-10-22       Impact factor: 22.113

2.  Hitting the bullseye with a nonlethal payload: resistance in CD123-positive malignancies.

Authors:  Lukasz P Gondek
Journal:  J Clin Invest       Date:  2019-11-01       Impact factor: 14.808

3.  Accelerated lymphocyte reconstitution and long-term recovery after transplantation of lentiviral-transduced rhesus CD34+ cells mobilized by G-CSF and plerixafor.

Authors:  Naoya Uchida; Aylin Bonifacino; Allen E Krouse; Mark E Metzger; Gyorgy Csako; Agnes Lee-Stroka; Ross M Fasano; Susan F Leitman; Joseph J Mattapallil; Matthew M Hsieh; John F Tisdale; Robert E Donahue
Journal:  Exp Hematol       Date:  2011-04-15       Impact factor: 3.084

4.  Nephrin forms a complex with adherens junction proteins and CASK in podocytes and in Madin-Darby canine kidney cells expressing nephrin.

Authors:  Sanna Lehtonen; Eero Lehtonen; Krystyna Kudlicka; Harry Holthöfer; Marilyn G Farquhar
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

Review 5.  T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia.

Authors:  Armen Mardiros; Stephen J Forman; Lihua E Budde
Journal:  Curr Opin Hematol       Date:  2015-11       Impact factor: 3.284

6.  Prospective isolation of human clonogenic common myeloid progenitors.

Authors:  Markus G Manz; Toshihiro Miyamoto; Koichi Akashi; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-22       Impact factor: 11.205

Review 7.  Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3.

Authors:  Nan Li; Madeline R Spetz; Dan Li; Mitchell Ho
Journal:  Pharmacol Ther       Date:  2021-05-14       Impact factor: 13.400

8.  Mathematical modeling reveals differential effects of erythropoietin on proliferation and lineage commitment of human hematopoietic progenitors in early erythroid culture.

Authors:  Daniel Ward; Deborah Carter; Martin Homer; Lucia Marucci; Alexandra Gampel
Journal:  Haematologica       Date:  2015-11-20       Impact factor: 9.941

9.  CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies.

Authors:  Ugo Testa; Elvira Pelosi; Arthur Frankel
Journal:  Biomark Res       Date:  2014-02-10

10.  Altered neutrophil immunophenotypes in childhood B‑cell precursor acute lymphoblastic leukemia.

Authors:  Elen Oliveira; Thiago S Bacelar; Juana Ciudad; Maria Cecília M Ribeiro; Daniela R N Garcia; Lukasz Sedek; Simone F Maia; Daniel B Aranha; Indyara C Machado; Arissa Ikeda; Bianca F Baglioli; Nathalia Lopez-Duarte; Lisandra A C Teixeira; Tomasz Szczepanski; Maria Luiza M Silva; Marcelo G P Land; Alberto Orfao; Elaine S Costa
Journal:  Oncotarget       Date:  2016-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.